Carmence Ho

ORCID: 0009-0005-0042-5230
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Neutrophil, Myeloperoxidase and Oxidative Mechanisms
  • Chronic Myeloid Leukemia Treatments
  • Macrophage Migration Inhibitory Factor
  • Immune Cell Function and Interaction
  • Cancer Research and Treatments
  • Cell Adhesion Molecules Research
  • Immune cells in cancer
  • Cancer Immunotherapy and Biomarkers
  • Structural Behavior of Reinforced Concrete
  • Peptidase Inhibition and Analysis
  • Melanoma and MAPK Pathways
  • CAR-T cell therapy research
  • Monoclonal and Polyclonal Antibodies Research
  • Phagocytosis and Immune Regulation
  • Acute Myeloid Leukemia Research
  • Ferroptosis and cancer prognosis
  • IL-33, ST2, and ILC Pathways
  • Cytokine Signaling Pathways and Interactions
  • Immunotherapy and Immune Responses
  • NF-κB Signaling Pathways
  • Veterinary medicine and infectious diseases
  • Lymphoma Diagnosis and Treatment

NGM Biopharmaceuticals (United States)
2022-2024

We recently reported that resistance to PD-1 blockade in a refractory lung cancer-derived model involved increased collagen deposition and the collagen-binding inhibitory receptor leukocyte-associated immunoglobulin-like 1 (LAIR1). Thus, we hypothesized LAIR1 cooperated suppress therapeutic response. In this study, report is associated with tumor stroma highly expressed by intratumoral myeloid cells both human tumors mouse models of cancer. Stroma-associated exhibit suppressive phenotype...

10.1158/1535-7163.mct-23-0866 article EN Molecular Cancer Therapeutics 2024-04-22

Solid tumors are dense three-dimensional (3D) multicellular structures that enable efficient receptor-ligand trans interactions via close cell-cell contact. Immunoglobulin-like transcript (ILT)2 and ILT4 related immune-suppressive receptors play a role in the inhibition of myeloid cells within tumor microenvironment. The relative contribution ILT2 to immune context solid tissue has not been fully explored. We present evidence both contribute inhibition. found although inhibits cell...

10.1158/2326-6066.cir-23-0568 article EN Cancer Immunology Research 2024-02-23

Abstract Background: Myeloid immune suppression in the tumor microenvironment is known to contribute evasion. ILT2 (aka LILRB1) and ILT4 LILRB2) are distinct ITIM-containing immunosuppressive receptors that recognize shared MHC-I ligands. Both highly expressed on infiltrating myeloid cells, while also tumor-associated T NK cells. Furthermore, both upregulated patients who do not respond cell checkpoint inhibitor therapy, implicating these as potential resistance mechanisms. Given their...

10.1158/1538-7445.am2021-lb156 article EN Cancer Research 2021-07-01
Coming Soon ...